Utah has a long tradition of medical innovation, so it's no wonder that these visionary startups, Clene Nanomedicine, Curza and Reddyport, are pioneering novel breakthrough therapies and technologies.


"Much larger pharmaceutical companies have failed in their quest to develop better drugs for MS, ALS and Parkinson's. If Clene succeeds, patients will benefit, while Utah will witness the rise of a new, global biopharmaceutical company."

--Rob Etherington, President & CEO, Clene Nanomedicine

Using a patented nano (super small) technology, called Clean-Surface Nanosuspension[TM], Clene Nanomedicine (Clene) is developing first-in-class, innovative drugs to help treat diseases like multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's. These are nanocrystal drugs, which are in a much smaller form than traditional drugs, resulting in better absorption, potentially faster efficacy, and fewer side effects.

Clene's lead product, CNM-Au8, is the only nanocrystal drug to be studied in pre-clinical animal models of demyelination and neurodegeneration. It is also the only nanocrystal drug that's received FDA approval for both Phase 1 and Phase 2 human clinical trials, and has been granted orphan drug designation for ALS by the FDA.

Demyelination, the damage or loss of the myelin sheath surrounding nerve cells, is a critical component of major neurological disorders in the central nervous system, such as MS. Encouraging results for the repair of myelin have been achieved with CNM-Au8. For MS, this myelin repair could delay or reverse disease progression.

As a startup, Clene had a choice of where to locate. After a short initial beginning in California's Silicon Valley, Rob Etherington, president &. CEO moved the company to Holladay, near Salt Lake City, at the base of the Wasatch Mountains. He was impressed by Utah's business-friendly climate, thriving economy, talent, and wonderful quality of life.

Clene has a vision for a pharmaceutical future that will give new hope to patients with neurodegenerative diseases. That future could be closer than you think.


"Curza is waging war on the worldwide superbug crisis - developing the first new class of antibiotics in over 20 years to fight drug-resistant bacteria, and we're proudly making it happen in Utah."

--Ryan Davies, CEO, Curza

Resistance is rapidly rising to commonly used antibiotics. In fact, the World Health Organization...

To continue reading

Request your trial